VIVUS Initiates Pivotal Phase 3 Trial In Obese Patients And Announces Qnexa Dose

VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has initiated the first of two pivotal phase 3 studies of Qnexa in obese patients. The EQUIP study (OB-302) will enroll morbidly obese patients with Body Mass Index (”BMI”) that equals or exceeds 35. [click link for full article]

More: continued here

Filed under: Clinical Trials on November 12th, 2007